Spots Global Cancer Trial Database for A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
Official Title: A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
Study ID: NCT04405505
Conditions
Study Description
Brief Summary: This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus paclitaxel for injection (albumin bound) in subjects with advanced triple negative breast cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Chinese Academy of Medical Sciencesand Peking Union Medical College Hospital, Beijing, Beijing, China
Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Chongqing Cancer Hospital, Chongqing, Chongqing, China
The First Affilited Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi Zhuang Autonomous Region, China
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
The fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Affiliated Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, China
AnYang Tumor Hospital, Anyang, Henan, China
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Hunan Cancer Hospital, Changsha, Hunan, China
Nantong Tumor Hospital, Nantong, Jiangsu, China
The First Hospital of Jilin University, Changchun, Jilin, China
Yanbian University Hospital, Yanji, Jilin, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
Shanxi Cancer Hospital, Taiyuan, Shanxi, China
The Second Affiliated Hospital of PLA Airforce Military Medical University, Xi'an, Shanxi, China
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
Shanxi Provincial People's Hospital, Xi'an, Shanxi, China
The Second People's Hospital of Neijiang, Neijiang, Sichuan, China
Tianjin Cancer Hospital, Tianjin, Tianjin, China
Xinjiang Uiger Municipal People's Hospital, Urumqi, Xinjiang, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
